- Equity Espresso
- Posts
- Nanosonics (ASX: NAN) Broker Ratings
Nanosonics (ASX: NAN) Broker Ratings
Equity Espresso
March 24, 2025 • Estimated Reading Time: 3 minutes
Nanosonics Broker Ratings
Updated: March 24, 2025
Nanosonics (ASX: NAN) announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for its innovative CORIS® system. The first phase of commercialisation remains on track for the first quarter of fiscal 2026 (Q1 FY26)
Nanosonics Broker Ratings
Date | Broker | Rating | Price Target |
|---|---|---|---|
21/03/2025 | Morgans | Add | $5.50 |
21/03/2025 | Ord Minnett | Accumulate | $4.55 |
24/02/2025 | Citi | Neutral | $4.55 |
21/02/2025 | Bell Potter | Hold | $4.06 |
21/03/2025
Morgans raised Nanosonics' target price to $5.50 from $4.50 following FDA approval of its Coris flexible endoscope, highlighting the significant market opportunity and competitive advantages this represents. Nanosonics retains its "key stock to watch" status with an Add rating from Morgans.
Ord Minnett reports the FDA has granted De Novo clearance for Nanosonics' Coris device, which automates flexible endoscope cleaning and reprocessing. The analyst expects this approval to enhance investor confidence and sentiment, with a European launch planned for Q1 2026, followed by North American availability in 2H 2026.
24/02/2025
Citi raised its target for Nanosonics to $4.55 from $3.40 while maintaining a Neutral rating after 1H25 results aligned with pre-announced figures and management upgraded FY25 guidance on stronger sales and favourable currency effects.
Bell Potter raises its target for Nanosonics to $4.06 from $3.45 while maintaining a Hold rating following 1H25 results showing 18% revenue growth from a weak prior period. US revenues increased 17% year-over-year and 3% sequentially, with Bell Potter considering the latter a better performance indicator.
Want more stock market information like this?
Sign up for our daily stock market newsletter:
DISCLAIMER: Please note that the information provided in this newsletter is for educational purposes only and should not be considered financial advice. It is not intended to encourage you to buy/sell assets or make economic decisions. We strongly recommend conducting your own research before making any investment.